IDEAYA Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M |
| Operating expenses | $378.0M | $334.0M | $157.8M | $113.4M | $78.2M |
| Cash from operations | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M |
| Capital expenditure | $2.4M | $3.9M | $2.4M | $3.4M | $2.6M |
| Free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M | -$58.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.1B | $1.1B | $649.3M | $388.0M | $381.3M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M |
Shares outstanding 87.9M · Free float 91.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.